G207 and PVSRIPO treatment of medulloblastoma and pediatric high grade glioma

HSV G207 and polio:rhinovirus PVSRIPO are two different viral immunotherapies used to treat malignant brain tumors in children. While some patients experience durable survival with these viral immunotherapies, many children have no response. The purpose of this work is to explore these viral immunotherapies in pediatric high grade glioma (pHGG) and medulloblastoma in order to elucidate how tumor response to treatment and to identify putative biomarkers of response and therapeutic targets. Overall design: Four different medulloblastoma cell lines treated with either G207 or PVSRIPO for 0, 8, or 24 hours. 2 different pediatric high grade glioma cell lines treated with G207 for 0, 8, or 24 hours.